In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...

To remain relevant in an interconnected ecosystem, biopharma must go beyond optimising yesterday’s markets and begin ...

A favorable appeals court ruling repositioned a coalition of universities and Nobel laureates to win credit for inventing a ...

Using the gene scissors CRISPR and stem cells, researchers at Stockholm University and the UK Dementia Research Institute (UK ...

The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell ...

Researchers at UC Berkeley’s Innovative Genomics Institute, or IGI, developed a revolutionary treatment using CRISPR-Cas9 gene editing technology for an infant born with a rare genetic disease ...

ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, May 19, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene ...

vacated the Patent Trial and Appeal Board’s (PTAB) prior determination that the University of California lacked conception of CRISPR-Cas9 editing in eukaryotic cells before the Broad Institute.

SRSD107 Phase 1 Clinical Results: Sustained, dose-dependent pharmacodynamic response to therapy A Phase 2 clinical trial of SRSD107 is being initiated ... The Nobel Prize-winning CRISPR technology has ...

The CRISPR-led gene-editing revolution is set to begin next month in its first ever trial in humans ... than current PD-1–targeted drugs as the technology directly knocks-out the gene ...

Addressing the distinction between conception and reduction to practice and the requirement for written description in the ...

And despite their relative simplicity, they deploy remarkably savvy defensive strategies against viral invaders. The most well-known is CRISPR-Cas9, adapted for human use as the first FDA-approved ...